Sponsors (2)
The bill expands and coordinates precision oncology services for veterans and funds a national registry and sequencing platform—improving care and research—but does so at measurable taxpayer cost while concentrating services, creating implementation and privacy risks, and imposing administrative strains on the VA.
Veterans with prostate or other genitourinary cancers gain coordinated access to precision oncology (genetic sequencing, clinical trials, and specialized care) at designated VA Centers, with travel support for eligible patients.
VA patients and providers get a national prostate cancer registry and a uniform sequencing platform, improving care coordination, data quality, and research that can accelerate better treatments and clinical-trial matching.
The bill authorizes funding ($15.5M/year for FY2027–FY2029) and mandates staffing and research positions to expand VA capacity for advanced cancer care and research.
Taxpayers face increased federal spending (authorized $15.5M/year FY2027–FY2029) plus additional implementation and ongoing costs that may not be fully captured by the authorization.
Concentrating advanced services in at least 21 designated Centers risks reduced access for veterans at non-designated or rural VA facilities, requiring travel and potentially worsening timely local care despite travel support rules.
Mandated staffing, new infrastructure, and contracting/development requirements (sequencing platform, registry) increase administrative and procurement burdens on the VA; combined with the 60‑day planning deadline, this could lead to rushed or incomplete plans and costly revisions that strain staff and divert local resources.
Based on analysis of 3 sections of legislative text.
Establishes a VA precision oncology program for prostate cancer with 21+ Centers of Excellence, a national sequencing platform, and a prostate cancer registry, authorizing $15.5M/year for FY2027–FY2029.
Creates a VA Precision Oncology Program for prostate cancer that designates at least 21 VA Centers of Excellence, builds a national prostate cancer registry and a uniform genetic sequencing platform, coordinates clinical trials and research, and funds the program $15.5 million per year for FY2027–FY2029. The law requires the VA to set up program leadership (based at the Seattle VA Medical Center), submit an implementation plan within 60 days, produce annual reports, maintain center designations for multi‑year terms, and protect existing prostate cancer staff/program funding through January 1, 2030.
Official title: To direct the Secretary of Veterans Affairs to establish a precision oncology program for cancer of the prostate, and for other purposes.
Introduced April 28, 2026 by Gregory Francis Murphy · Last progress April 28, 2026